The $1 billion financing that followed Monday's trial win carries a 2029 redemption trigger and funds factory capacity years ahead of a filing. The cash math puts the size of the raise in context.
The most revealing part of Vaxcyte's new financing is not its $1 billion size. It is a clause that lets the company retire its new bonds early if the stock runs well past the conversion price, a structure that works in shareholders' favor if the stock keeps rising.
Vaxcyte, the developer of a 31-strain pneumococcal vaccine, launched two underwritten deals shortly after Monday's close: $500 million of common stock and pre-funded warrants, and $500 million of senior unsecured convertible notes maturing . Underwriters can take an extra $75 million of each. Neither deal depends on the other.
The bond terms
The notes pay interest twice a year at a rate still to be fixed. Vaxcyte can settle conversions in cash, stock or a mix. From , it can redeem the notes if its shares trade above 130% of the conversion price for a set period, effectively forcing holders to convert. For shareholders, that caps how long the debt overhang can last in a bull case. For bondholders, it caps their upside.
What the cash buys
Clinical spending is only part of the plan. The company named its two remaining adult Phase 3 trials, a manufacturing consistency study and an infant Phase 2 study, then went further: scale-up of production, "additional manufacturing capacity," inventory built ahead of a possible launch, and medical, commercial and systems spending tied to what it called "the anticipated U.S. launch of VAX-31 in adults."
The timetable makes that unusual. Results from the last two adult trials are due in the first half of 2027, and a biologics license application is planned for the first half of 2028.
Runway, by the numbers
At the first-half pace, existing cash reaches roughly mid-2028, the same window as the planned filing. The new money pushes that out by about nine months, and further if the convertible option is exercised. With quarterly spending up about 34% year over year, the cushion is thinner than the headline balance suggests.
Dilution and the January benchmark
At Monday's closing price of $73.82, the stock tranche equals about 6.8 million shares, around 4.7% of the share count. That price sits 47.6% above the $50 at which Vaxcyte sold 11 million shares in January, so the company is issuing at a far better level than nine months ago.
Investors had already taken some air out of the rally. The stock opened Monday at $87.21, touched $90.75, then closed near the day's low after a 30.7% gain. It indicated about 3% lower before Tuesday's open.
What the pricing will reveal
The pricing release is the next data point. A thin discount on the shares and a rich conversion premium on the notes would show investors willing to fund manufacturing well before an FDA decision. A wide discount would show they want to be paid for carrying regulatory risk that has not yet been retired.